Exploring Potential Proteomic Biomarkers for Prognosis of Infective Endocarditis through Profiled Autoantibodies by an Immunomics Protein Array Technique
Protein Biomarkers for Infective Endocarditis
Keywords:Infective endocarditis , protein array, prognostic biomarkers
Though infective endocarditis (IE) is a life-threatening cardiac infection with a high mortality rate, the effective diagnostic and prognostic biomarkers for IE are still lacking. The aim of this study was to explore the potential applicable proteomic biomarkers for IE through the Immunome™ Protein Array system. The system was employed to profile those autoantibodies in IE patients and control subjects. Our results showed that interleukin-1 alpha (IL1A), nucleolar protein 4 (NOL4), tudor and KH domain-containing protein (TDRKH), G antigen 2B/2C (GAGE2), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and X antigen family member 2 (XAGE2) are highly differentially-expressed among IE and non-IE control. Furthermore, bactericidal permeability-increasing protein (BPI), drebrin-like protein (DBNL), signal transducing adapter molecule 2 (STAM2), cyclin-dependent kinase 16 (CDK16), BAG family molecular chaperone regulator 4 (BAG4), and nuclear receptor-interacting protein 3 (NRIP3) are differentially-expressed among IE and healthy controls. On the other hand, those previously identified biomarkers for IE, including erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, procalcitonin, and N-terminal-pro-B-type natriuretic peptide demonstrated only minor significance. With scientific rationalities for those highly differentially-expressed proteins, they could serve as potential candidates for diagnostic biomarkers of IE for further analysis.
Beynon RP, Bahl VK, Prendergast BD. 2006. Infective endocarditis. BMJ 333:334-9.
Chen CH. 1997. Nosocomial Infective Endocarditis: Four Cases Report. J Infect Dis Soc ROC. 8:76-9.
Chen CH, Chang IL, Wang SH, et al. 2020. Potential Novel Proteomic Biomarkers for Diagnosis of Vertebral Osteomyelitis Identified Using an Immunomics Protein Array Technique: Two Cases Reports. Medicine (Baltimore) (revised).
Chen CH, Lo MC, Hwang K, et al. 2001. Infective endocarditis with neurologic complications: 10-year experience. J Microbiol Immunol Infect. 34:119-24.
Chen CH, Tsai CD, Wu SL, et al. 2001. A retrospective study of infective endocarditis at Changhua Christian Hospital during the years 1989-1999. J Intern Med Taiwan. 12:177-83.
Cornelissen CG, Frechen DA, et al. 2013. Inflammatory parameters and prediction of prognosis in infective endocarditis. BMC Infect Dis. 13:272.
Gu Z, Eils R, Schlesner M. 2016. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics (Oxford, England). 32:2847-9.
Habib G, Hoen B, Tornos PT, et al. 2009. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J. 30:2369-413.
Habib G, Lancellotti P, Antunes MJ, et al. 2015. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 36:3075-128.
Knudsen JB, Fuursted K, Petersen E, et al. 2009. Infective endocarditis: a continuous challenge. The recent experience of a European tertiary center. J Heart Valve Dis.18:386-94.
Kocazeybek B, Kucukoglu S, Oner YA. 2003. Procalcitonin and C-reactive protein in infective endocarditis: correlation with etiology and prognosis. Chemotherapy. 49:76-84.
Koscielny G, An P, Carvalho-Silva D, et al. 2017. Open Targets: a platform for therapeutic target identification and validation. Nucleic Acids Res. 45:D985-D94.
Lang RM, Bierig M, Devereux RB, et al. 2005. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 18:1440-63.
Li JS, Sexton DJ, Mick N, et al. 2000. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30:633-8.
Liu N, Xing R, Yang C, et al. 2014. HIP-55/DBNL-dependent regulation of adrenergic receptor mediates the ERK1/2 proliferative pathway. Molecular bioSystems. 10:1932-9.
Nelson D, Goldstein JM, Boatright K, et al. 2001. pH-regulated secretion of a glyceraldehyde-3-phosphate dehydrogenase from Streptococcus gordonii FSS2: purification, characterization, and cloning of the gene encoding this enzyme. J Dent Res. 80:371-7.
Nishimura RA, Otto CM, Bonow RO, et al. 2014. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 63:2438-88.
Snipsoyr MG, Ludvigsen M, Petersen E, et al. 2016. A systematic review of biomarkers in the diagnosis of infective endocarditis. Int J Cardiol. 202:564-70.
Teles C, Smith A, Lang S. 2012. Antibiotic modulation of the plasminogen binding ability of viridans group streptococci. Antimicrob Agents Chemother. 56:458-63.
Thiene G, Basso C. 2006. Pathology and pathogenesis of infective endocarditis in native heart valves. Cardiovasc Pathol. 15, 256-263.
Ward Jr JH. 1965. Hierarchical grouping to optimize an objective function J Am Stat Assoc. 58:236-44.
Watkin RW, Harper LV, Vernallis AB, et al. 2007. Pro-inflammatory cytokines IL6, TNF-alpha, IL1beta, procalcitonin, lipopolysaccharide binding protein and C-reactive protein in infective endocarditis. J Infect. 55:220-5.
Wei XB, Chen F, Huang JL, et al. 2017. Novel Risk Biomarker for Infective Endocarditis Patients With Normal Left Ventricular Ejection Fraction—Monocyte to High-Density Lipoprotein Cholesterol Ratio. Circ J. 82, 283-288.
Yim G, Wang HH, Davies J. 2006. The truth about antibiotics. Int J Med Microbiol. 296:163-70.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).